Hugues Dolgos

1.1k total citations
26 papers, 792 citations indexed

About

Hugues Dolgos is a scholar working on Pharmacology, Oncology and Computational Theory and Mathematics. According to data from OpenAlex, Hugues Dolgos has authored 26 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 10 papers in Oncology and 8 papers in Computational Theory and Mathematics. Recurrent topics in Hugues Dolgos's work include Pharmacogenetics and Drug Metabolism (16 papers), Drug Transport and Resistance Mechanisms (8 papers) and Computational Drug Discovery Methods (8 papers). Hugues Dolgos is often cited by papers focused on Pharmacogenetics and Drug Metabolism (16 papers), Drug Transport and Resistance Mechanisms (8 papers) and Computational Drug Discovery Methods (8 papers). Hugues Dolgos collaborates with scholars based in Germany, United States and Sweden. Hugues Dolgos's co-authors include Sheila Annie Peters, Carl Petersson, Yan Li, Ken Page, Lars Weidolf, J. Gerry Kenna, Richard A. Thompson, Ian D. Wilson, Emre M. Isin and Richard Weaver and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Biochemistry and Clinical Pharmacology & Therapeutics.

In The Last Decade

Hugues Dolgos

26 papers receiving 761 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hugues Dolgos Germany 16 392 227 208 186 80 26 792
Rhys D.O. Jones United Kingdom 14 400 1.0× 306 1.3× 264 1.3× 243 1.3× 124 1.6× 32 925
Ragini Vuppugalla United States 16 458 1.2× 304 1.3× 214 1.0× 150 0.8× 116 1.4× 27 898
Rowan Stringer Switzerland 17 267 0.7× 216 1.0× 232 1.1× 99 0.5× 59 0.7× 23 874
Ken Grime United Kingdom 18 557 1.4× 404 1.8× 271 1.3× 188 1.0× 96 1.2× 36 1.1k
Hiroshi Komura Japan 17 286 0.7× 273 1.2× 245 1.2× 100 0.5× 71 0.9× 40 817
Philip Wastall United States 6 525 1.3× 349 1.5× 350 1.7× 196 1.1× 138 1.7× 8 1.2k
Sharon L. Ripp United States 22 569 1.5× 269 1.2× 390 1.9× 100 0.5× 73 0.9× 30 1.3k
Susan Cole United Kingdom 14 290 0.7× 268 1.2× 276 1.3× 200 1.1× 103 1.3× 28 916
Stephen Fowler Switzerland 22 560 1.4× 314 1.4× 321 1.5× 149 0.8× 73 0.9× 47 1.1k
Louis Leung United States 16 287 0.7× 163 0.7× 195 0.9× 117 0.6× 49 0.6× 24 754

Countries citing papers authored by Hugues Dolgos

Since Specialization
Citations

This map shows the geographic impact of Hugues Dolgos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugues Dolgos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugues Dolgos more than expected).

Fields of papers citing papers by Hugues Dolgos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugues Dolgos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugues Dolgos. The network helps show where Hugues Dolgos may publish in the future.

Co-authorship network of co-authors of Hugues Dolgos

This figure shows the co-authorship network connecting the top 25 collaborators of Hugues Dolgos. A scholar is included among the top collaborators of Hugues Dolgos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugues Dolgos. Hugues Dolgos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peters, Sheila Annie, Carl Petersson, Andree Blaukat, Joern-Peter Halle, & Hugues Dolgos. (2020). Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies. Drug Discovery Today. 25(5). 909–919. 12 indexed citations
2.
Sun, Dajun, et al.. (2019). Evaluating the Role of Solubility in Oral Absorption of Poorly Water‐Soluble Drugs Using Physiologically‐Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics. 107(3). 650–661. 55 indexed citations
3.
Peters, Sheila Annie & Hugues Dolgos. (2019). Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them. Clinical Pharmacokinetics. 58(11). 1355–1371. 55 indexed citations
4.
Petersson, Carl, et al.. (2017). A comparative evaluation of models to predict human intestinal metabolism from nonclinical data. Biopharmaceutics & Drug Disposition. 38(3). 163–186. 25 indexed citations
5.
Dolgos, Hugues, et al.. (2016). Translational Medicine Guide transforms drug development processes: the recent Merck experience. Drug Discovery Today. 21(3). 517–526. 42 indexed citations
6.
Dolgos, Hugues, et al.. (2016). In vitro and in vivo drug disposition of cilengitide in animals and human. Pharmacology Research & Perspectives. 4(2). e00217–e00217. 8 indexed citations
7.
8.
Karlsson, Fredrik, et al.. (2013). Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development. Drug Metabolism and Disposition. 41(12). 2033–2046. 31 indexed citations
9.
Hilgendorf, Constanze, Mareike Lutz, Philippe Bachellier, et al.. (2013). Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors. Xenobiotica. 44(1). 17–27. 9 indexed citations
10.
Javornik, Ana, et al.. (2013). Comparison of thein vitroandin vivometabolism of Cladribine (Leustatin, Movectro) in animals and human. Xenobiotica. 43(12). 1084–1094. 8 indexed citations
11.
Thompson, Richard A., Emre M. Isin, Yan Li, et al.. (2012). In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. Chemical Research in Toxicology. 25(8). 1616–1632. 153 indexed citations
12.
Ballard, Peter, Patrick Brassil, Khanh Bui, et al.. (2012). The right compound in the right assay at the right time: an integrated discovery DMPK strategy. Drug Metabolism Reviews. 44(3). 224–252. 37 indexed citations
13.
Peters, Sheila Annie, Patricia Schroeder, Nagdeep Giri, & Hugues Dolgos. (2012). Evaluation of the Use of Static and Dynamic Models to Predict Drug-Drug Interaction and Its Associated Variability: Impact on Drug Discovery and Early Development. Drug Metabolism and Disposition. 40(8). 1495–1507. 38 indexed citations
14.
15.
Thompson, Richard A., Emre M. Isin, Yan Li, et al.. (2010). Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chemico-Biological Interactions. 192(1-2). 65–71. 69 indexed citations
16.
Gabrielsson, Johan, et al.. (2009). Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discovery Today. 14(7-8). 358–372. 74 indexed citations
17.
Thelingwani, Roslyn, Simbarashe Zvada, Hugues Dolgos, Anna‐Lena Ungell, & Collen Masimirembwa. (2009). In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions. Drug Metabolism and Disposition. 37(6). 1286–1294. 21 indexed citations
18.
Richert, Lysiane, Gregor Tuschl, Catherine Viollon‐Abadie, et al.. (2008). Species Differences in the Response of Liver Drug-Metabolizing Enzymes to (S)-4-O-Tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric Acid (EMD 392949) in Vivo and in Vitro. Drug Metabolism and Disposition. 36(4). 702–714. 23 indexed citations
19.
Krösser, Sonja, et al.. (2006). Investigation of sarizotan’s impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. European Journal of Clinical Pharmacology. 62(4). 277–284. 23 indexed citations
20.
Delaforge, Marcel, François André, Maryse Jaouen, et al.. (1997). Metabolism of Tentoxin by Hepatic Cytochrome P‐450 3A Isozymes. European Journal of Biochemistry. 250(1). 150–157. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rhys D.O. Jones Breakdown of academic impact, for papers by Ragini Vuppugalla Breakdown of academic impact, for papers by Rowan Stringer Breakdown of academic impact, for papers by Ken Grime Breakdown of academic impact, for papers by Hiroshi Komura Breakdown of academic impact, for papers by Philip Wastall Breakdown of academic impact, for papers by Sharon L. Ripp Breakdown of academic impact, for papers by Susan Cole Breakdown of academic impact, for papers by Stephen Fowler Breakdown of academic impact, for papers by Louis Leung
Rankless by CCL
2026